This month, Viatris is to realize a significant commercial boost for its interchangeable biosimilar Semglee (insulin glargine-yfgn) in the US, with the product having moved to preferred status on pharmacy benefit manager Express Scripts’ largest national formulary from 1 January 2022. (Also see "Viatris’ Interchangeable Semglee Lands On Express Scripts Formulary" - Generics Bulletin, 22 October, 2021.)
Prime Therapeutics, a PBM which serves nearly 33 million people and is collectively owned by 19 Blue Cross and Blue...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?